Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Ph.D., University of Michigan, Ann Arbor 1966
• 

  Previous Appointments & Affiliations

  • Consulting Professor in Nursing, School of Nursing, Duke University 1999 - 2003
  • Instructor, Temporary in the School of Nursing, School of Nursing, Duke University 1999
• Research
• 

  Selected Grants

  • Clinical Research Management Program for Nurses awarded by Health Resources and Service Administration 2006 - 2009
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Dren, A. T., and G. H. Turner. “The drug development process: Challenges, changes, and careers. Part I.” Advance for Nurses 2, no. 20 (2000): 20–22.
    • Dren, A. T., and G. H. Turner. “The drug development process: Challenges, changes, and careers. Part II.” Advance for Nurses 2, no. 21 (2000): 18–28.
    • Anderson, G. D., M. K. Yau, B. E. Gidal, S. J. Harris, R. H. Levy, A. A. Lai, K. B. Wolf, W. A. Wargin, and A. T. Dren. “Bidirectional interaction of valproate and lamotrigine in healthy subjects.” Clinical Pharmacology and Therapeutics 60, no. 2 (August 1996): 145–56. https://doi.org/10.1016/s0009-9236(96)90130-7.
       Full Text
    • Risner, M. E., G. P. Womble, A. T. Dren, and P. K. Manasco. “Long-term clinical trial experience with Lamictal (lamotrigine) treatment of epilepsy.” Epilepsia 36, no. Suppl 4 (1995): 66.
    • Bergen, D., R. Ristanovic, D. Rudd, A. T. Dren, and K. Klein. “Placebo-controlled evaluation of clinical laboratory data and body weight during administration of Lamictal in outpatients with partial seizures.” Epilepsia 35, no. Suppl 8 (1994): 1963.
    • Matsuo, F., D. Bergen, E. Faught, J. A. Messenheimer, A. T. Dren, G. D. Rudd, and C. G. Lineberry. “Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.” Neurology 43, no. 11 (November 1993): 2284–91. https://doi.org/10.1212/wnl.43.11.2284.
       Full Text  Link to Item
    • Dren, A. T., M. E. Risner, G. P. Womble, M. K. Yau, G. D. Rudd, and C. G. Lineberry. “Placebo-controlled add-on experience demonstrating the safety and efficacy of lamotrigine in patients with refractory partial seizures.” Journal of Clinical Pharmacology 32 (1992): 766.
    • Rudd, G. D., A. T. Dren, G. P. Womble, M. E. Risner, and C. G. Lineberry. “Comparison of crossover and parallel designs in the clinical evaluation of lamotrigine.” Pharmacotherapy 12 (1992): 263.
    • Borison, R. L., B. I. Diamond, and A. T. Dren. “Does sigma receptor antagonism predict clinical antipsychotic efficacy?” Psychopharmacology Bulletin 27, no. 2 (January 1991): 103–6.
    • DREN, A. T., D. M. EBERT, E. J. WARAWA, and P. W. DODGE. “INTRAVENOUS ANESTHETIC ACTIVITY OF BICYCLIC KETALS STRUCTURALLY RELATED TO KETAMINE AND ETOXADROL.” Pharmacology Biochemistry and Behavior 28, no. 1 (September 1, 1987): 122–122.
       Link to Item
    • Dren, A. T., C. W. Gorodetzky, and A. Cato. “Case report: The case of the disappearing white blood cells.” J Clin Res Drug Dev 1 (1987): 79–86.
    • WHITE, H. L., and A. T. DREN. “SOME PRECLINICAL AND CLINICAL PHARMACOLOGICAL PROPERTIES OF BW-A616U, A REVERSIBLE MAO-A INHIBITOR.” Clinical Neuropharmacology 9 (January 1, 1986): 561–62.
       Link to Item
    • Davidson, J., A. Dren, R. Miller, P. Manberg, C. Kilts, and M. Wingfield. “BW234U: a non-dopamine receptor blocking antipsychotic drug without extrapyramidal effects?” Drug Development Research 6, no. 1 (1985): 13–17.
    • Schwarcz, Glenn, Angelos Halaris, Anthony Dren, and Paul Manberg. “Open label evaluation of the novel antipsychotic compound BW234U in chronic schizophrenics.” Drug Development Research 5, no. 4 (1985): 387–93. https://doi.org/10.1002/ddr.430050412.
       Full Text
    • Warawa, E., A. T. Dren, and D. M. Ebert. “Synthesis and intravenous general anesthetic activity of 7-aza-II, 12-dioxxa-6-phenuyltricyclo-7,2,1,0 dodecanes.” Journal of Medicinal Chemistry 28 (1985).
    • Feighner, J. P., A. T. Dren, and P. J. Manberg. “Clinical experience with a new antipsychotic without dopamine blocking properties.” Clin Neuropharmacol 7, no. Suppl 1 (1984): 148–49.
    • Lee, C. M., H. E. Zaugg, R. J. Michaels, A. T. Dren, N. P. Plotnikoff, and P. R. Young. “New azacannabinoids highly active in the central nervous system.” Journal of Medicinal Chemistry 26, no. 2 (February 1983): 278–80. https://doi.org/10.1021/jm00356a031.
       Full Text
    • Guy, W., G. Manov, W. H. Wilson, T. A. Ban, O. K. Fjetland, P. J. Manberg, and A. T. Dren. “Psychotropic actions of BW 234U in the treatment of inpatient schizophrenics: A dose‐range study.” Drug Development Research 3, no. 3 (January 1, 1983): 245–52. https://doi.org/10.1002/ddr.430030306.
       Full Text
    • Davidson, J., R. Miller, M. Wingfield, W. Zung, and A. T. Dren. “The first clinical study of BW-234U in schizophrenia.” Psychopharmacol Bull 18, no. 4 (October 1982): 173–76.
       Link to Item
    • Minard, F. N., J. C. Cain, D. S. Grant, and A. T. Dren. “N-o-Methoxyphenylpiperazine: a simple blocker of dopaminergic receptors in the brain.” The Journal of Pharmacy and Pharmacology 31, no. 2 (February 1979): 91–93. https://doi.org/10.1111/j.2042-7158.1979.tb13439.x.
       Full Text
    • Bopp, B. A., A. T. Dren, D. M. Ebert, and A. O. Geiszler. “Local anesthetic activity and acute toxicity of N-heptyl-1,2,3,4-tetrahydro-6-methoxy-1-naphthylamine methanesulfonate.” Journal of Pharmaceutical Sciences 67, no. 6 (June 1978): 882–84. https://doi.org/10.1002/jps.2600670648.
       Full Text
    • Dren, A. T., B. A. Bopp, D. M. Ebert, A. O. Geiszler, J. B. Holland, B. W. Horrom, and D. A. Dunnigan. “Local anesthetic activity and acute toxicity of N-substituted 1,2,3,4-tetrahydro-1- and 2-naphthylamines.” Journal of Pharmaceutical Sciences 67, no. 6 (June 1978): 880–82. https://doi.org/10.1002/jps.2600670647.
       Full Text
    • Lee, C. M., R. J. Michaels, H. E. Zaugg, A. T. Dren, N. P. Plotnikoff, and P. R. Young. “Cannabinoids. Synthesis and central nervous system activity of 8-substituted 10-hydroxy-5,5-dimethyl-5H-[1]benzopyrano[4,3-c]pyridine and derivatives.” Journal of Medicinal Chemistry 20, no. 11 (November 1977): 1508–11. https://doi.org/10.1021/jm00221a031.
       Full Text
    • Kirkpatrick, W. E., T. Okabe, I. W. Hillyard, R. K. Robins, A. T. Dren, and T. Novinson. “3-Halo-5,7-dimethylpyrazolo [1,5-a]pyrimidines, a nonbenzodiazepinoid class of antianxiety agents devoid of potentiation of central nervous system depressant effects of ethanol or barbiturates.” Journal of Medicinal Chemistry 20, no. 3 (March 1977): 386–93. https://doi.org/10.1021/jm00213a014.
       Full Text
    • Razdan, R. K., B. Z. Terris, H. G. Pars, N. P. Plotnikoff, P. W. Dodge, A. T. Dren, J. Kyncl, and P. Somani. “Drugs derived from cannabinoids. 2. Basic esters of nitrogen and carbocyclic analogs.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 454–61. https://doi.org/10.1021/jm00226a002.
       Full Text
    • Razdan, R. K., G. R. Handrick, H. C. Dalzell, J. F. Howes, M. Winn, N. P. Plotnikoff, P. W. Dodge, and A. T. Dren. “Drugs derived from cannabinoids. 4. Effect of alkyl substitution in sulfur and carbocyclic analogs.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 552–54. https://doi.org/10.1021/jm00226a023.
       Full Text
    • Razdan, Raj K., B. Zitko Terris, G. R. Handrick, Haldean C. Dalzell, H. G. Pars, J. F. Howes, Nicholas P. Plotnikoff, Patrick W. Dodge, and Anthony T. Dren. “Drugs derived from cannabinoids. 3. Sulfur analogs, thiopyranobenzopyrans and thienobenzopyrans.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 549–51. https://doi.org/10.1021/jm00226a022.
       Full Text
    • Winn, Martin, David Arendsen, Patrick W. Dodge, Anthony Dren, Daniel Dunnigan, Robert Hallas, Kao Hwang, Jaroslav Kyncl, and Yien-Hwei Lee. “Drugs derived from cannabinoids. 5. .DELTA.6a,10a,-Tetrahydrocannabinol and heterocyclic analogs containing aromatic side chains.” Journal of Medicinal Chemistry 19, no. 4 (April 1976): 461–71. https://doi.org/10.1021/jm00226a003.
       Full Text
    • Dren, A. T., and E. F. Domino. “Cholinergic and adrenergic activating agents as antagonists of the EEG effects of hemicholinium-3.” Archives Internationales De Pharmacodynamie Et De Therapie 175, no. 1 (September 1968): 63–72.
    • Dren, A. T., and E. F. Domino. “Effects of hemicholinium (HC-3) on EEG activation and brain acetylcholine in the dog.” The Journal of Pharmacology and Experimental Therapeutics 161, no. 1 (May 1968): 141–54.
    • Rosecrans, J. A., A. T. Dren, and E. F. Domino. “Effects of physostigmine on rat brain acetylcholine, acetylcholinesterase and conditioned pole jumping.” International Journal of Neuropharmacology 7, no. 2 (March 1968): 127–34. https://doi.org/10.1016/0028-3908(68)90006-3.
       Full Text
    • Domino, E. F., K. Yamamoto, and A. T. Dren. “Role of cholinergic mechanisms in states of wakefulness and sleep.” Progress in Brain Research 28 (January 1968): 113–33. https://doi.org/10.1016/s0079-6123(08)64547-1.
       Full Text
    • Dren, A. T. “EEG Evaluation of Drug Action.” Intek 4 (1968): 1–3.
    • Domino, E. F., A. T. Dren, and K. I. Yamamoto. “Pharmacologic evidence for cholinergic mechanisms in neocortical and limbic activating systems.” Progress in Brain Research 27 (January 1967): 337–64. https://doi.org/10.1016/s0079-6123(08)63109-x.
       Full Text
• Teaching & Mentoring
• 

  Recent Courses

  • NURSING 580: Nurse as Scholar I: Science Development, Study Design & Statistics 2022
  • NURSING 580: Nurse as Scholar I: Science Development, Study Design & Statistics 2021
  • NURSING 580: Nurse as Scholar I: Science Development, Study Design & Statistics 2020

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.